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report a case of MAC-related IRIS of the CNS in an HIV-infected patient who presented with
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>100 cells/mL for 1 year. Cases of MAC-related IRIS of the CNS reported in the literature are
reviewed.
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Disseminated Mycobacterium avium complex (MAC) infec-
tion, an important AIDS-defining opportunistic infection
commonly occurring in patients with CD4 lymphocyte
counts <50 cells/mL, is associated with significant
morbidity and mortality, and with shortened survival.1,2
With the introduction of highly active antiretroviral
therapy (HAART) in 1996, the incidences of opportunistic
infections, including disseminated MAC (DMAC) infection,
and AIDS-related mortality and hospitalization dramatically
declined in HIV-infected patients.3 The beneficial effects of
HAART result from gradual restoration of pathogen-specific
immune responses, mediated by suppression of HIV-1
replication and increases of CD4 counts.4,5 However,
adverse clinical phenomena, including paradoxical wors-
ening of treated opportunistic infections or unmasking of
previously subclinical untreated infections, may develop
during the initial months, or even years6 of HAART. These
atypical presentations have since been recognized as
inflammatory reactions directed at quiescent opportunistic
pathogens following CD4 increases with HAART, otherwise
known as immune reconstitution inflammatory syndrome
(IRIS). MAC-related IRIS most commonly presents as focal
lymphadenitis without mycobacteremia, with or without
suppuration.7e10 Cerebral MAC infection is very uncommon,
and MAC-related IRIS of the central nervous system (CNS) is
even rarer.11,12 Herein, we present a case of an HIV-1
infected patient who developed an unusual and poten-
tially devastating meningoencephalitis and myelitis due to
MAC infection almost 17 months after commencing effec-
tive HAART and one year after attaining a sustained rise of
CD4 cell count >100 cells/mL. Reported cases of MAC-
related IRIS of the CNS in the literature are reviewed with
the aim of better understanding of the rare form of IRIS
associated with DMAC infection.
Case report
The 23-year-old homosexual man with HIV infection who
was diagnosed in 2006 presented with intermittent fevers
and oral candidiasis. HAART was prescribed in April 2008
but he did not continue this treatment due to severe nausea
and vomiting. He began to have abdominal fullness, weight
loss and intermittent fevers since August 2008 and
computed tomography of the abdomen disclosed prominent
ascites, marked splenomegaly and multiple confluent
enlarged lymphadenopathies in the retroperitoneum and
para-aortic regions in October 2008. Excisional biopsy of
the inguinal lymph node only revealed histiocytosis.
Progressive abdominal distension and dyspnea developed
later and chest radiography showed massive left pleural
effusion. The CD4 count was 2 cells/mL, and the plasma HIV
RNA load (PVL) 77600 copies/mL in November 2008. After
admission, HAART with abacavir/lamivudine and lopinavir/
ritonavir was initiated and antiMAC therapy was begun with
moxifloxacin, amikacin, clarithromycin and ethambutol
when MAC was isolated from cultures of pleural effusion,
lung biopsy, blood, ascites, bone marrow, and stool speci-
mens. In the following months, the patient had been well
and PVL was <50 copies/mL and a CD4 count >100 cells/mLon several occasions for more than one year. Given the
clinical stability of the patient after about 14 months of
antiMAC therapy and his significant immunological response
to HAART, antiMAC therapy was discontinued in February
2010.
In April 2010, the patient presented with a one-week
history of low back pain, easily stumbling, and progressive
paraplegia. The physical examination revealed an ill-
looking man who was afebrile, drowsy, and had neck stiff-
ness and a decrease in muscle power of the bilateral lower
extremities. Laboratory investigations showed a CD4 count
of 70 cells/mL, PVL<50 copies/mL and a serum cryptococcal
antigen titer of <1:2; the remainders were otherwise
normal. A magnetic resonance imaging disclosed numerous
tiny enhancing nodules diffusely scattered in the bilateral
cerebral and cerebellar hemispheres, deep gray matter,
brain stem and whole spinal cord (Fig. 1). A lumbar punc-
ture revealed opening pressure, 230 mmH2O; white cells,
6/mL (L/N, 6/0); protein, 141 mg/dL; and glucose, 32 mg/
dL. Under the tentative diagnosis of MAC meningoenceph-
alitis and myelitis, levofloxacin, clarithromycin, ethambutol
and rifabutin were resumed. Adjunctive dexamethasone
was added at a dose of 4 mg before antiMAC therapy was
given with subsequent daily dose of 16 mg. After 5 days of
therapy, the patient’s consciousness totally recovered and
muscle power significantly improved. A second lumbar
puncture showed opening pressure, 52 mmH2O; white cell,
0; protein, 48 mg/dL; and glucose, 58 mg/dL. MAC was
subsequently cultured from both blood and cerebrospinal
fluid specimens and he was discharged well on the 29th
hospital day. The patient remained stable on the antiMAC
therapy after discharge.Discussion
In the present case, the patient initially presented with
DMAC infection with mycobacteremia, pneumonia,
empyema, and peritonitis. After commencing HAART and
continuation of antimycobacterial regimen, good virolog-
ical response and gradual restoration of immune function
were observed. According to the guidelines for prevention
and treatment of opportunistic infections in HIV-infected
adults and adolescents13 antiMAC therapy that had been
given for 14 months with satisfactory resolution of symp-
toms in our case was ceased after the patient fulfilled the
criteria for discontinuing secondary prophylaxis of DMAC
infection. However, new onset of neurological symptoms
and signs occurred 2 months after ceasing antiMAC therapy
despite adequate immunity, which is consistent with
a diagnosis of MAC-related CNS-IRIS.
Diagnosis of IRIS of the CNS is difficult because IRIS
remains a clinical syndrome with variable presentations and
severities, and pathologic and microbiologic investigations
of the CNS involvement are limited by potential morbidity
related to the diagnostic procedures. According to clinical
features defined by Riedel and colleagues14 our patient
fulfills his working definition, except without confirmation
by histopathology that may demonstrate T-cell infiltration.
Our arguments for MAC-related CNS-IRIS in this case are as
follows. First, the immune reconstitution was documented
by a sustained increase in CD4 count >100 cells/mL for one
Figure 1. Magnetic resonance scan of the brain and spinal
cord demonstrating numerous tiny enhanced nodules scattered
diffusely.
70 Y.-C. Lee et al.year, a level at which DMAC disease would be less likely to
occur in HIV-infected patients. Second, our patient had risk
factors for the development of IRIS, which include a high
baseline PVL and a lower baseline CD4 count before initi-
ation of HAART, rapid decline in PVL after HAART, a highantigenic burden and disseminated infection, initiation of
HAART concurrently with or soon after initiation of anti-
microbial therapy of an acute infection, and being anti-
retroviral-naı¨ve.15 Although MAC could be cultured from
affected tissue, French et al16 and Shelburne et al17 do not
consider mycobacteremia as criteria of exclusion for MAC-
related IRIS.
Typically most cases of mycobacteria-associated CNS-
IRIS occur within 5 to 10 months after HAART is
commenced.18e20 The present case of MAC-related CNS-IRIS
is unique because of its late development after HAART, and
because of the CNS localization. MAC-associated CNS-IRIS in
HIV-infected patients is rare and a search of the PubMed
database (English language publications) identified four
reported cases of CNS infection related to IRIS due to MAC
infection in patients with AIDS.12,21e23 The clinical presen-
tations and relationship to timing of HAART of the five cases
(including the present case) are shown in Table 1.12,21e23 All
reported cases were male and the median age of the
patients was 36 years (range, 24e51 years). The presenting
neurological symptoms included headache (2 patients),
visual disturbance (1), aphasia (1), disorientation (1),
drowsy consciousness (2), and paraplegia (1). The image
study of the brain demonstrated hypodensities or ring-
enhancing lesions of varying size. Manifestations of IRIS
developed after a median of 17 months of HAART (range,
2e25 months). Patients had a median CD4 count of 20 cells/
mL (range, 2e80 cells/mL) at baseline and a median plasma
HIV viral load of 7.8  104 copies/mL (range, 1.4 
104e3.9  105 copies/mL) before beginning HAART. At the
time IRIS was diagnosed, the CD4 count had increased to
a median of 70 cells/mL (range, 10e210 cells/mL) and the
PVL had decreased to below the lower limit of detection in
all of the patients. MAC was isolated from affected tissue in
four of the five patients and only our patient had docu-
mented mycobacteremia. Corticosteroids were prescribed
in addition to antimycobacterial drugs in two patients and
all-cause mortality rate was 40% (2/5).
MAC-related IRIS may be clinically indistinguishable from
active infection, and is mostly benign and self-limiting;
however, severe cases and death have been described.23
Optimal management of the various presentations of MAC-
related IRIS of the CNS remains poorly defined because
there are no well-conducted randomized treatment trials
for these complications related to HAART. Generally,
continuation of HAART is recommended and most deterio-
rating conditions will improve gradually. Use of cortico-
steroids does not yet document a mortality benefit but is
indicated for catastrophic CNS-IRIS in patients who have
massive inflammation, resulting in impending brain herni-
ation.24 In our patient, rapid improvement of neurological
symptoms after addition of steroids was observed (about
5 days), which suggests the disease entity as fulminant
inflammation involving the CNS, instead of relapsing
infection.
The reported incidence of relapsing MAC disease in HIV-
infected patients receiving HAART after the interruption of
maintenance therapy is very low25and relapses are often
observed in patients who fail to respond to, or stop, HAART
other than to MAC-IRIS. There are well-known guidelines
that recommend when to discontinue primary and
secondary prophylaxis for several opportunistic infections
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MAC infection and IRIS 71in AIDS patients with HAART-related immune reconstitu-
tion.13 In the present case, antimycobacterial regimens
were discontinued when CD4 count had increased to the
recommended cut-off value for discontinuation of prophy-
laxis for MAC infection, although MAC-associated IRIS of the
CNS developed. Therefore, clinicians must always be more
cautious when stopping maintenance therapy for MAC
disease and remain alert for atypical presentations. Given
the potentially devastating consequences of such an
immune reconstitution, we should understand this disease
entity more, even if the overall occurrence of MAC disease
is still rare after ceasing secondary prophylaxis in HIV-
infected patients with good response to HAART.References
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